Home
About
Overview
Management Team
Board of Directors
Partners
Product Pipeline
Overview
Actimab-A
ATNM-400
Iomab-ACT for Gene & Cell Therapy Conditioning
Iomab-B
Clinical Trial Information
Publications
Actinium-225 Technology
R&D Technology & Platform
Investors
Investor Relations
Overview
News / Events
Press Releases
IR Calendar
Video Gallery
Email Alerts
Company Info
Profile
Presentations & Webinars
Contacts
Analyst Coverage
FAQ
Stock Data
Quote
Charts
Historical Data
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Governance
Board of Directors
Board Committees
Governance Documents
Careers
Contact
Targeted Radiotherapies for Patients with Unmet Needs
Actimab-A: CD33 targeting, mutation agnostic r/r AML therapeutic
ATNM-400: First-in-Class, Non-PSMA Prostate Cancer Therapeutic
Targeted Conditioning and Targeted Radiotherapy Pipeline
Actinium-225 Manufacturing Technology
Investor Relations
Careers
Contact Us
